Prediction of postchemotherapy ovarian function using markers of ovarian reserve

Oncologist

Volumn 19, Issue 1, 2014, Pages 68-74

  Henry, N Lynn ^a   Xia, Rong ^b   Schott, Anne F ^a   McConnell, Daniel ^b   Banerjee, Mousumi ^b   Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anti M llerian hormone; Breast cancer; Chemotherapy; Ovarian function

Indexed keywords

ANTI-MÜLLERIAN HORMONE; BREAST CANCER; CHEMOTHERAPY; OVARIAN FUNCTION;

ADULT; ANTI-MULLERIAN HORMONE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; INHIBINS; MIDDLE AGED; OVARY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 84892585499     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0145     Document Type: Article

References (23)

1. Goodwin PJ, Ennis M, Pritchard KI et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999; 17: 2365-2370.
2. Ganz PA, Rowland JH, Desmond K et al. Life after breast cancer: Understanding women's healthrelated quality of life and sexual functioning. J Clin Oncol 1998; 16: 501-514.
3. Shuster LT, Rhodes DJ, Gostout BS et al. Premature menopause or early menopause: Long-term health consequences. Maturitas 2010; 65: 161-166.
4. Petrek JA, Naughton MJ, Case LD et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol 2006; 24: 1045-1051.
5. Sukumvanich P, Case LD, Van Zee K et al. Incidence and time course of bleeding after longterm amenorrhea after breast cancer treatment: A prospective study. Cancer 2010; 116: 3102-3111.
6. Fanchin R, Schonäuer LM, Righini C et al. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003; 18: 323-327.
7. van Rooij IA, Broekmans FJ, te Velde ER et al. Serum anti-Müllerian hormone levels: A novel measure of ovarian reserve. Hum Reprod 2002; 17: 3065-3071.
8. van Rooij IA, Broekmans FJ, Scheffer GJ et al. Serum antimullerianhormone levels best reflect the reproductive decline with age in normal women with proven fertility: A longitudinal study. Fertil Steril 2005; 83: 979-987.
9. Pellicer A, Ardiles G, Neuspiller F et al. Evaluation of the ovarian reserve in young low responders with normal basal levels of follicle-stimulating hormone using three-dimensional ultrasonography. Fertil Steril 1998; 70: 671-675.
10. Anders C, Marcom PK, Peterson B et al. A pilot study of predictive markers of chemotherapyrelatedamenorrheaamongpremenopausalwomen with early stage breast cancer. Cancer Invest 2008; 26: 286-295.
11. Anderson RA, Cameron DA. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011; 96: 1336-1343.
12. Lee SJ, Schover LR, PartridgeAHet al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917-2931.
13. Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy forwomen with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3784-3796.
14. Smith IE, Dowsett M, Yap Y-S et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines. J Clin Oncol 2006; 24: 2444-2447.
15. Burstein HJ, Mayer E, Patridge AH et al. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: Cases and lessons. Clin Breast Cancer 2006; 7: 158-161.
16. Randolph JF Jr, Sowers M, Gold EB et al. Reproductive hormones in the early menopausal transition: Relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab 2003; 88: 1516-1522.
17. Santoro N, Crawford SL, Allsworth JE et al. Assessing menstrual cycles with urinary hormone assays. Am J Physiol Endocrinol Metab 2003; 284: E521-E530.
18. Santen RJ, Demers L, Ohorodnik S et al. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 2007; 72: 666-671.
19. Partridge AH, Ruddy KJ, Gelber S et al. Ovarian reserve inwomenwho remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 2010; 94: 638-644.
20. Su HI, Sammel MD, Green J et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 2010; 116: 592-599.
21. Yu B, Douglas N, Ferin MJ et al. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 2010; 116: 2099-2105.
22. Henry NL, Xia R, Banerjee M et al. Predictors of recovery of ovarian function during aromatase inhibitor therapy. Ann Oncol 2013; 24: 2011-2016.
23. Su HI, Chung K, SammelMDet al. Antral follicle count provides additive information to hormone measures fordetermining ovarian function in breast cancer survivors. Fertil Steril 2011; 95: 1857-1859.